論文・技術情報追加のお知らせ

1. Surveillance of Maternal Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccines in the Vaccine Adverse Event Reporting System-United States, July 1, 2015-September 30, 2023.

妊婦へのTdapワクチン接種の安全性をVAERSデータで評価。

対象DB：FAERS,VAERS

2. Impact of Reporter Type on Signal Detection of Cancer Therapy-Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System.

報告者の属性ががん治療薬の脱毛シグナル検出に与える影響。

対象DB：FAERS

3. Psychiatric Adverse Events and Administration Challenges Associated with GLP-1 Receptor Agonists for Weight Loss: A Real-World Analysis.

GLP-1受容体作動薬の精神副作用と投与上の課題をFAERSで解析。

対象DB：FAERS

4. Cardiovascular Safety Signals of Oral Versus Topical Minoxidil in FAERS: A Disproportionality Analysis (Analytic Cohort 2012-2025).

ミノキシジルの経口対外用の心血管安全性シグナルを比較解析。

対象DB：FAERS

5. A Pharmacovigilance Analysis of Ocular Adverse Events Associated with GLP-1 Receptor Agonists.

GLP-1受容体作動薬に関連する眼の副作用の不均衡解析。

対象DB：FAERS

6. Disproportionality Analysis of Hematologic Adverse Event Signals Associated with Venetoclax in Combination with Senescence-Inducing Chemotherapy.

ベネトクラク併用療法に関連する血液毒性シグナルの不均衡解析。

対象DB：FAERS

7. Identification of Drug Repurposing Opportunities of Immunomodulatory Drugs for Inflammatory Bowel Disease Through Inverse Pharmacovigilance Signal Detection in the FAERS Database.

免疫調節薬の炎症性腸疾患への適応外転用の可能性を特定。

対象DB：FAERS

8. Drug-associated torsades de pointes and QT prolongation in infants: A focused real-world disproportionality analysis pharmacovigilance study.

乳児における薬剤性TdPおよびQT延長のリアルワールド解析。

対象DB：FAERS

9. CAR-T therapy-associated infections in hematologic malignancies: a real-world pharmacovigilance analysis.

血液がんのCAR-T療法に関連する感染症のリアルワールド解析。

対象DB：FAERS

10. Ocular toxicity associated with anti-CD20 monoclonal antibodies: A pharmacovigilance analysis using the FAERS database.

抗CD20モノクローナル抗体に関連する眼毒性のFAERS解析。

対象DB：FAERS

11. Machine Learning Model for Predicting Severe Adverse Events in Oncology Patients Using the US Food and Drug Administration Adverse Event Reporting System.

機械学習を用い、がん患者の重篤な副作用をFAERSから予測。

対象DB：FAERS

12. Chronic Kidney Disease Amplifies Gabapentin-Associated Dementia Risk: Evidence for a Renal Pharmacokinetic Mechanism.

慢性腎臓病がガバペンチン関連認知症リスクを増大させる可能性。

対象DB：FAERS

13. Adverse Drug Event Profile of Radiocontrast Iodine in Elderly: A Retrospective Focused Pharmacovigilance-Based Disproportionality Analysis Study.

高齢者におけるヨード造影剤の副作用プロファイルを解析。

対象DB：FAERS

14. Not All GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety.

GLP-1受容体作動薬の内分泌および皮膚副作用の薬剤間差異。

対象DB：FAERS,KAERS

15. Vigilance for drug safety of darolutamide in the cancer therapies: a disproportionality analysis from the FDA Adverse Event Reporting System.

がん治療におけるダロルタミドの安全性をFAERSで不均衡解析。

対象DB：FAERS

16. Disproportionality analysis of adverse events associated with endothelin receptor antagonists based on the FDA adverse event reporting system (FAERS).

エンドセリン受容体拮抗薬の副作用をFAERSデータに基づき解析。

対象DB：FAERS

17. Hydrochlorothiazide and chlorthalidone use and glaucoma risk: pharmacovigilance analysis and nationwide cohort study.

ヒドロクロロチアジド等の使用と緑内障リスクの関連を解析。

対象DB：FAERS,KAERS

18. Risk factors for drug-related gastrointestinal ulcer:a retrospective pharmacovigilance study.

薬剤性胃腸潰瘍のリスク因子に関するレトロスペクティブ解析。

対象DB：FAERS

19. Comparative pharmacovigilance of non-benzodiazepine receptor agonists versus dual orexin receptor antagonists for insomnia in older adults.

非ベンゾ系睡眠薬とオレキシン受容体拮抗薬の安全性比較。

対象DB：FAERS

20. Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis.

一般的な糖尿病薬の性的副作用に関するFAERS不均衡解析。

対象DB：FAERS

21. Real-world safety assessment of avacopan in patients with antineutrophil cytoplasmic antibody-associated vasculitis.

ANCA関連血管炎患者におけるアバコパンのリアルワールド評価。

対象DB：FAERS

22. Eosinophilia-related adverse events reporting associated with medications: a disproportionality and regression analysis of the FDA Adverse Event Reporting System.

薬剤に関連する好酸球増多症の副作用報告を不均衡解析。

対象DB：FAERS

23. Cardiac disorders associated with compound long-acting bronchodilators for inhalation: a pharmacovigilance analysis of the FDA adverse event reporting system database.

吸入用長時間作用性気管支拡張配合剤と心疾患の関連を解析。

対象DB：FAERS

24. Selective serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor use and sexual dysfunction: a pharmacovigilance analysis.

SSRI/SNRIの使用と性機能障害の不均衡解析および記述的分析。

対象DB：FAERS

25. Mavacamten and atrial fibrillation: assessing the risk through FAERS and meta-analysis.

マバカムテンと心房細動リスクの関連をFAERS等で評価。

対象DB：FAERS

26. Evaluating the safety profile of alpha-1 blockers, 5alpha-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS).

前立腺肥大症治療薬3種の安全性をFAERSデータに基づき解析。

対象DB：FAERS

27. Global trends and forecasts of cervical cancer and a real-world safety assessment of human papillomavirus vaccines in women: A systematic analysis of the Global Burden of Disease study 2021 and the Vaccine Adverse Event Reporting System database.

子宮頸がんの動向予測とHPVワクチンのリアルワールド安全性評価。

対象DB：FAERS,VAERS

28. GLP-1 receptor agonists and sexual function in women and men: a narrative review of emerging evidence and the need for further research.

GLP-1受容体作動薬と男女の性機能に関する証拠のレビュー。

対象DB：FAERS

29. Comparison of Adverse Events Associated With Six Common Antibiotics in Lower Respiratory Tract Infections Using the United States Food and Drug Administration Adverse Event Reporting System.

下気道感染症への主要抗菌薬6種の副作用をFAERSで比較解析。

対象DB：FAERS

30. Profiles of neuropsychiatric toxicity associated with different endocrine therapies for breast cancer: a global pharmacovigilance study based on FAERS and VigiAccess.

乳がんの各種内分泌療法に関連する神経精神毒性のプロファイル。

対象DB：FAERS

31. Comprehensive Pharmacovigilance Analysis of Lebrikizumab: A Real-World Safety Assessment Based on the FDA Adverse Event Reporting System (FAERS) Database.

レブリキズマブの市販後安全性をFAERSデータに基づき包括解析。

対象DB：FAERS

32. Disseminated Intravascular Coagulation Following Idarucizumab and Andexanet Alfa: Assessment of a Signal of Disproportionate Reporting From the Food and Drugs Administration Adverse Event Reporting System (FAERS) Database.

イダルシズマブ等投与後の播種性血管内凝固（DIC）の評価。

対象DB：FAERS

33. Adverse events associated with drug-related thiamine deficiency: A pharmacovigilance study.

薬剤性チアミン欠乏症に関連する副作用の薬物監視研究。

対象DB：FAERS

34. Muscle atrophy associated with glucagon-like Peptide-1 receptor agonists: A population-based observational study.

GLP-1受容体作動薬に関連する筋萎縮の住民ベースの観察研究。

対象DB：FAERS

35. Post-marketing safety evaluation of the live-attenuated chikungunya vaccine (IXCHIQ).

生ポリオ・チクングニアワクチンの市販後安全性評価。

対象DB：CVAR,EudraVigilance,FAERS,VAERS

36. Post-marketing safety surveillance and adverse event risk factors of abemaciclib: a pharmacoepidemiologic study.

アベマシクリブの市販後安全性監視と副作用リスク因子の解析。

対象DB：FAERS

37. Pharmacovigilance analysis of the FGFR inhibitor futibatinib using the FDA adverse event reporting system (FAERS) database.

FGFR阻害薬フチバチニブの副作用をFAERSデータを用いて解析。

対象DB：FAERS

38. Female Sexual Dysfunction Induced by Second-Generation Antipsychotic Drugs-A Disproportionality Analysis Based on the FAERS Database.

第2世代抗精神病薬による女性の性機能障害の不均衡解析。

対象DB：FAERS

39. Adverse events of romidepsin versus tucidinostat for peripheral T-cell lymphoma: a pharmacovigilance study using the Japanese adverse drug event report database.

末梢性T細胞リンパ腫治療薬2種の副作用をFAERSで比較解析。

対象DB：JADER

40. From Pharmacovigilance Signals to Mechanistic Phenotypes: Integrating ADMET, PK/PD, and Network Context to Interpret Antiviral Safety in Pregnancy.

薬物監視シグナルから作用機序を解明する統合的アプローチ。

対象DB：EudraVigilance

41. Asthma Reporting with Anti-TNFalpha Drugs used in Inflammatory Joint Diseases: A Vigibase(R) Study with Disproportionality Analysis.

炎症性関節疾患への抗TNFα薬使用に伴う喘息報告のVigibase研究。

対象DB：VigiBase

42. Real-world safety profile of T-cell engagers: evidence from multi-database analysis with CAR-T comparisons.

T細胞エンゲージャーの安全性プロファイルをCAR-T等と比較。

対象DB：VigiBase

43. Aortic dissection during the perinatal period in women with Marfan-related disorders: a retrospective cohort study using the Japanese Diagnosis Procedure Combination database.

マルファン症候群関連疾患を持つ女性の周産期大動脈解離の調査。

対象DB：DPC

44. Association between betamimetics tocolysis duration and maternal adverse events: a national real-world data analysis from Japan.

ベータ刺激薬による切迫早産治療期間と母体副作用の関連。

対象DB：DPC

45. Variation in transitional care implementation patterns for older adults with stroke in Japan: A retrospective observational study.

日本における脳卒中高齢者の移行期ケア実施パターンの変遷。

対象DB：JMDC

46. Treatment Patterns in Hospitalized Hip Fracture Patients: An Interrupted Time-Series Analysis Around the New Fee for Secondary Fracture Prevention in Japan.

日本の股関節骨折入院患者の治療パターンの変遷をDPCで解析。

対象DB：MDV

47. Real-world sequential treatment patterns and outcomes in the new era of immunotherapy for advanced gastric cancer in Japan.

日本の進行胃がん免疫療法時代における逐次治療パターンと予後。

対象DB：MDV

48. Adherence to Biologic Therapies is Associated with Improved Clinical Outcomes and Reduced Healthcare Resource Utilization in Patients with Severe Asthma in Japan.

生物学的製剤のアドヒアランス向上による臨床成績と医療費の改善。

対象DB：MDV

49. Diagnosis of inflammatory bowel disease following symptomatic faecal immunochemical testing - A population based cohort study.

糞便免疫化学検査後の炎症性腸疾患の診断に関する住民研究。

対象DB：CPRD

50. Trends and inequalities in advice and guidance versus direct referral in NHS primary care, 2015-23: population based study.

英国NHSにおける専門医への助言・指導と直接紹介の傾向を分析。

対象DB：CPRD

51. Evaluating Arrhythmia Risk in Patients with Chronic Obstructive Pulmonary Disease Treated with Aclidinium/Formoterol Fumarate and Other Inhaled Bronchodilators: A Post-Authorization Safety Study.

アクリジニウム等で治療中のCOPD患者における不整脈リスク評価。

対象DB：CPRD

52. Management of People with Asthma in Primary Care by Smoking Status: A Cohort Study.

喫煙状態別の喘息患者に対するプライマリケア管理のコホート研究。

対象DB：CPRD

53. First trimester antidepressant use and miscarriage.

妊娠第1三半期の抗うつ薬使用と流産リスクの関連。

対象DB：CPRD

54. Association of Autosomal Dominant Polycystic Kidney Disease With Incident Aortic Dissection or Aneurysm.

常染色体優性多嚢胞腎と大動脈解離・瘤発症の関連を解析。

対象DB：DeSC